Background: Recently, it was shown that the relation between admission glucose and functional outcome after ischemic stroke is described by a J-shaped curve, with a glucose range of 3.7–7.3 mmol/l associated with a favorable outcome. We tested the hypothesis that persistence of hyperglycemia above this threshold at 24–48 h after stroke onset impairs 3-month functional outcome. Methods: We analyzed all patients with glucose >7.3 mmol/l on admission from the Acute STroke Registry and Analysis of Lausanne (ASTRAL). Patients were divided into two groups according to their subacute glucose level at 24–48 h after last well-being time (group 1: ≤7.3 mmol/l, group 2: >7.3 mmol/l). A favorable functional outcome was defined as a modified Rankin Score (mRS) ≤2 at 3 months. A multiple logistic regression analysis of multiple demographic, clinical, laboratory and neuroimaging covariates was performed to assess predictors of an unfavorable outcome. Results: A total of 1,984 patients with ischemic stroke were admitted between January 1, 2003 and October 20, 2009, within 24 h after last well-being time. In the 421 patients (21.2%) with admission glucose >7.3 mmol/l, the proportion of patients with a favorable outcome was not statistically significantly different between the two groups (59.2 vs. 48.7%, respectively). In multiple logistic regression analysis, unfavorable outcome was significantly associated with age (odds ratio, OR: 1.06, 95% confidence interval, 95% CI: 1.03–1.08 for every 10-year increase), National Institute of Health Stroke Score, NIHSS score, on admission (OR: 1.16, 95% CI: 1.11–1.21), prehospital mRS (OR: 12.63, 95% CI: 2.61–61.10 for patients with score >0), antidiabetic drug usage (OR: 0.36, 95% CI: 0.15–0.86) and glucose on admission (OR: 1.16, 95% CI: 1.02–1.31 for every 1 mmol/l increase). No association was found between persistent hyperglycemia at 24–28 h and outcome in either diabetics or nondiabetics. Conclusions: In ischemic stroke patients with acute hyperglycemia, persistent hyperglycemia (>7.3 mmol/l) at 24–48 h after stroke onset is not associated with a worse functional outcome at 3 months whether the patient was previously diabetic or not.

Keywords:
Poststroke hyperglycemia, Glucose management, Acute ischemic stroke, Diabetes mellitus
1.
Quinn TJ, Lees KR: Hyperglycaemia in acute stroke – to treat or not to treat. Cerebrovasc Dis 2009;27(suppl 1):148–155.
2.
Oppenheimer SM, Hoffbrand BI, Oswald GA, Yudkin JS: Diabetes mellitus and early mortality from stroke. Br Med J (Clin Res Ed) 1985;291:1014–1015.
3.
Gray CS, Taylor R, French JM, Alberti KG, Venables GS, James OF, Shaw DA, Cartlidge NE, Bates D: The prognostic value of stress hyperglycaemia and previously unrecognized diabetes in acute stroke. Diabet Med 1987;4:237–240.
4.
Murros K, Fogelholm R, Kettunen S, Vuorela AL: Serum cortisol and outcome of ischemic brain infarction. J Neurol Sci 1993;116:12–17.
5.
Kruyt ND, Biessels GJ, Devries JH, Roos YB: Hyperglycemia in acute ischemic stroke: pathophysiology and clinical management. Nat Rev Neurol 2010;6:145–155.
6.
Van Kooten F, Hoogerbrugge N, Naarding P, Koudstaal PJ: Hyperglycemia in the acute phase of stroke is not caused by stress. Stroke 1993;24:1129–1132.
7.
Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25:457–507.
8.
Adams HP, Jr., del ZG, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF: Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007;38:1655–1711.
9.
Fuentes B, Ortega-Casarrubios MA, Sanjose B, Castillo J, Leira R, Serena J, Vivancos J, Davalos A, Gil-Nunez A, Egido J, Diez-Tejedor E: Persistent hyperglycemia >155 mg/dl in acute ischemic stroke patients: how well are we correcting it? Implications for outcome. Stroke 2010;41:2362–2365.
10.
Fuentes B, Castillo J, San JB, Leira R, Serena J, Vivancos J, Davalos A, Nunez AG, Egido J, Diez-Tejedor E: The prognostic value of capillary glucose levels in acute stroke: the GLycemia in Acute Stroke (GLIAS) study. Stroke 2009;40:562–568.
11.
Allport L, Baird T, Butcher K, Macgregor L, Prosser J, Colman P, Davis S: Frequency and temporal profile of poststroke hyperglycemia using continuous glucose monitoring. Diabetes Care 2006;29:1839–1844.
12.
Staszewski J, Brodacki B, Kotowicz J, Stepien A: Intravenous insulin therapy in the maintenance of strict glycemic control in nondiabetic acute stroke patients with mild hyperglycemia. J Stroke Cerebrovasc Dis 2010.
13.
Gray CS, Hildreth AJ, Sandercock PA, O’Connell JE, Johnston DE, Cartlidge NE, Bamford JM, James OF, Alberti KG: Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol 2007;6:397–406.
14.
Ntaios G, Egli M, Faouzi M, Michel P: J-shaped association between serum glucose and functional outcome in acute ischemic stroke. Stroke 2010;41:2366–2370.
15.
Michel P, Odier C, Rutgers M, Reichhart M, Maeder P, Meuli R, Wintermark M, Maghraoui A, Faouzi M, Croquelois A, Ntaios G: The Acute STroke Registry and Analysis of Lausanne (ASTRAL): design and baseline analysis of an ischemic stroke registry including acute multimodal imaging. Stroke 2010;41:2491–2498.
16.
Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160–3167.
17.
Kagansky N, Levy S, Knobler H: The role of hyperglycemia in acute stroke. Arch Neurol 2001;58:1209–1212.
18.
Parsons MW, Barber PA, Desmond PM, Baird TA, Darby DG, Byrnes G, Tress BM, Davis SM: Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol 2002;52:20–28.
19.
Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC: Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 2001;32:2426–2432.
20.
Woo J, Lam CW, Kay R, Wong AH, Teoh R, Nicholls MG: The influence of hyperglycemia and diabetes mellitus on immediate and 3-month morbidity and mortality after acute stroke. Arch Neurol 1990;47:1174–1177.
21.
Kes VB, Solter VV, Supanc V, Demarin V: Impact of hyperglycemia on ischemic stroke mortality in diabetic and non-diabetic patients. Ann Saudi Med 2007;27:352–355.
22.
De Silva DA, Ebinger M, Christensen S, Parsons MW, Levi C, Butcher K, Barber PA, Bladin C, Donnan GA, Davis SM: Baseline diabetic status and admission blood glucose were poor prognostic factors in the EPITHET trial. Cerebrovasc Dis 2010;29:14–21.
23.
Ntaios G, Egli M, Arsovska A, Joye D, Bettex Y, Lauber E, Eskandari A, D’Ambrogio S, Richoz B, Ruiz J, Michel P: An intravenous insulin protocol for strict glycemic control in acute ischaemic stroke. Eur J Neurol 2011, doi: 10.1111/j.1468–1331.2011.03537.x (Epub ahead of print).
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.